Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090.

Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090. Abstract Text:

Scott R Evans,Tzu-Min Yeh,Ned Sacktor,David B Clifford,David Simpson,Eric N Miller,Ronald J Ellis,Victor Valcour,Christina M Marra,Linda Millar,Giovanni Schifitto, ,Scott R Evans,Tzu-Min Yeh,Ned Sacktor,David B Clifford,David Simpson,Eric N Miller,Ronald J Ellis,Victor Valcour,Christina M Marra,Linda Millar,Giovanni Schifitto, ,Scott R Evans,Tzu-Min Yeh,Ned Sacktor,David B Clifford,David Simpson,Eric N Miller,Ronald J Ellis,Victor Valcour,Christina M Marra,Linda Millar,Giovanni Schifitto, ,

Objective: To assess the long-term safety (primary aim) and efficacy (secondary aim) of the MAO-B inhibitor Selegiline Transdermal System (STS) for the treatment of HIV-associated cognitive impairment. Background: HIV infection is associated with increased oxidative stress. In vitro and animal studies have shown that selegiline can reduce oxidative stress levels while enhancing the synthesis of neurotrophic factors. We conducted and reported a 24-week, double-blind, placebo-controlled study with STS in HIV-infected individuals with cognitive impairment (ACTG 5090). We now report the results of the 24-week open-label follow-up. Method: Subjects received either 3 mg/24 h or 6 mg/24 h STS daily. The primary efficacy endpoint was changes in the mean of z scores of six neuropsychological tests (NPZ-6). Additional outcomes included NPZ-8 and NPZ scores by cognitive domain. Results: 86 subjects were enrolled. There were few severe adverse experiences (n = 13). There was no significant change in NPZ-6 score, whereas significant changes were observed in NPZ-8 score and several cognitive domains. Conclusion: Long-term use of selegiline was safe and well tolerated in this HIV cohort of HIV with cognitive impairment. Cognitive improvement may be delayed in neuroprotective trials, suggesting that trials longer than 6 months may be necessary to assess the efficacy of putative neuroprotective agents.

Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090. Publishing Authors By Initials

SR Evans,TM Yeh,N Sacktor,DB Clifford,D Simpson,EN Miller,RJ Ellis,V Valcour,CM Marra,L Millar,G Schifitto, ,SR Evans,TM Yeh,N Sacktor,DB Clifford,D Simpson,EN Miller,RJ Ellis,V Valcour,CM Marra,L Millar,G Schifitto, ,SR Evans,TM Yeh,N Sacktor,DB Clifford,D Simpson,EN Miller,RJ Ellis,V Valcour,CM Marra,L Millar,G Schifitto, ,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: HIV clinical trials

VOLUME: 8

Page Numbers: 437-46

Journal Abbreviation:

ISSN: 1528-4336

DAY: 28

MONTH: 11

YEAR: 2007

Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100936377

Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090.

AFFILIATION: Harvard School of Public Health, Boston, Massachusetts, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: HIV Clin Trials

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Selegiline Transdermal System STS for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090 Related Publications

• Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.
• Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090.